Skip to main content
SpringerLink
Log in
Book cover

Biochemical Neurology pp 217–254Cite as

Disturbances of synaptic transmission

  • Chapter

  • 20 Accesses

Abstract

There appears to be more variety in the chemical substances involved in synaptic transmission than in those involved in any other single stage of neuro-physiological activity. This fact is utilized in clinical neuropharmacology, where an attempt is made to alter specific aspects of neural function selectively by pharmacological manipulation of individual neurotransmitters. Unlike the disorders so far considered in this book, disorders of neurotransmitter function all appear to be consequences of other disease processes. The natures of the primary disease processes are usually poorly understood. In general, disorders of synaptic transmission are more frequent and more important clinically than most of the disorders of other neurochemical mechanisms so far dealt with in this book.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Watkins, J. C. and Evans, R. H. (1981). Excitatory amino acid transmitters. Annu. Rev. Pharmacol. Toxicol., 21, 165–204

    CAS  PubMed  Google Scholar 

  2. Schwartz, J-C., Pollard, H. and Quach, T. T. (1980). Histamine as a neurotransmitter in mammalian brain: neurochemical evidence. J. Neurochem., 35, 26–35

    CAS  PubMed  Google Scholar 

  3. Fredholm, B. B. and Hedquist, P. (1980). Modulation of neurotransmission by purine nucleotides and nucleosides. Biochem. Pharmacol., 29, 1635–1643

    CAS  PubMed  Google Scholar 

  4. Calne, D. B. (1979). Neurotransmitters, neuromodulators, and neurohormones. Neurology, 29, 1517–1521

    CAS  PubMed  Google Scholar 

  5. O’Dea, R. F., Viveros, O. H. and Diliberto, E. J. Jr. (1981). Protein carboxymethylation: role in the regulation of cell functions. Biochem. Pharmacol., 30, 1163–1168

    PubMed  Google Scholar 

  6. Snyder, S. H. and Goodman, R. R. (1980). Multiple neurotransmitter receptors. J. Neurochem., 35, 5–15

    CAS  PubMed  Google Scholar 

  7. Starke, K. (1981). Presynaptic receptors. Annu. Rev. Pharmacol. Toxicol., 21, 7–30

    CAS  PubMed  Google Scholar 

  8. Cooper, J. R., Bloom, F. E. and Roth, R. H. (1978). The Biochemical Basis of Neuropharmacology. 3rd Edn. (New York: Oxford University Press)

    Google Scholar 

  9. Sterling, G. H. and O’Neill, J. J. (1978). Citrate as the precursor of the acetyl moiety of acetylcholine. J. Neurochem., 31, 525–530

    CAS  PubMed  Google Scholar 

  10. Cornford, E. M., Braun, L. D. and Oldendorf, W. H. (1978). Carrier mediated blood-brain barrier transport of choline and certain choline analogs. J. Neurochem., 30, 299–308

    CAS  PubMed  Google Scholar 

  11. Kuhar, M. J. and Murrin, L. C. (1978). Sodium-dependent, high affinity choline uptake. J. Neurochem., 30, 15–21

    CAS  PubMed  Google Scholar 

  12. Lindstrom, J. and Dau, P. (1980). Biology of myasthenia gravis. Annu. Rev. Pharmacol. Toxicol., 20, 337–362

    CAS  PubMed  Google Scholar 

  13. Michelson, M. J. and Danilov, A. F. (1971). Synaptic vesicles, specific granules, autopharma-cology. 5.1. Cholinergic transmissions. In Bacq, Z. M. (ed.) Fundamentals of Biochemical Pharmacology, pp. 221–253. (Oxford: Pergamon)

    Google Scholar 

  14. Iversen, L. L. (1974). Uptake mechanisms for neurotransmitter amines. Biochem. Pharmacol., 23, 1927–1935

    CAS  PubMed  Google Scholar 

  15. Eadie, M. J. and Tyrer, J. H. (1980). Anticonvulsant Therapy. Pharmacological Basis and Practice. 2nd Edn. (Edinburgh: Churchill-Livingstone)

    Google Scholar 

  16. Rowland, L. P. (1978). Myasthenia gravis. In Matthews, W. B. and Glaser, G. H. (eds.) Recent Advances in Clinical Neurology. Vol. 2, pp. 25–46. (Edinburgh: Churchill-Livingstone)

    Google Scholar 

  17. Simpson, J. A. (1977). Myasthenia gravis — validation of a hypothesis. Scott. Med. J., 22, 201–210

    CAS  PubMed  Google Scholar 

  18. Engel, A. G. and Santa, I. (1971). Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome. Ann. N. Y. Acad. Sci., 183, 46–63

    CAS  PubMed  Google Scholar 

  19. Lindstrom, J. M. and Lambert, E. H. (1978). Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis and Eaton-Lambert syndrome. Neurology, 28, 130–138

    CAS  PubMed  Google Scholar 

  20. Gutmann, L. and Pratt, L. (1976). Pathophysiologic aspects of human botulism. Arch. Neurol., 33, 175–179

    CAS  PubMed  Google Scholar 

  21. Wonnacott, S., Marchbanks, R. M. and Fiol, C. (1978). Ca2+ uptake by synaptosomes and its effect on the inhibition of acetylcholine release by botulinium toxin. J. Neurochem., 30, 1127–1134

    CAS  PubMed  Google Scholar 

  22. Harris, H. (1970). The Principles of Human Biochemical Genetics. (Amsterdam: North Holland)

    Google Scholar 

  23. McMillen, B. A., German, D. C. and Shore, P. A. (1980). Functional and pharmacological significance of brain dopamine and norepinephrine storage pools. Biochem. Pharmacol., 29, 3045–3050

    CAS  PubMed  Google Scholar 

  24. Kebabian, J. W. and Calne, D. B. (1979). Multiple receptors for dopamine. Nature (London), 277, 93–96

    CAS  Google Scholar 

  25. Seeman, P. (1980). Brain dopamine receptors. Pharmacol. Rev., 32, 230–313

    Google Scholar 

  26. Creese, I., Sibley, D. R., Leff, S. and Hamblin, M. (1981). Dopamine receptors: subtypes, localization and regulation. Fed. Proc, 40, 147–152

    CAS  PubMed  Google Scholar 

  27. Minneman, K. P. and Molinoff, P. B. (1980). Classification and quantitation of β-adrenergic receptor subtypes. Biochem. Pharmacol, 29, 1317–1323

    CAS  PubMed  Google Scholar 

  28. Starke, K., Taube, H. D. and Borowski, E. (1977). Presynaptic receptor systems in catechola-minergic transmission. Biochem. Pharmacol, 26, 259–268

    CAS  PubMed  Google Scholar 

  29. Demet, E. M. and Halaris, A. E. (1979). Origin and distribution of 3-methoxy-4-hydroxyphenylglycol in body fluids. Biochem. Pharmacol, 28, 3043–3049

    CAS  PubMed  Google Scholar 

  30. Ehringer, H. and Hornykewicz, O. (1960). Verteilung von Noradrenalin and Dopamin (3-Hydroxytryptamin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr., 38, 1236–1239

    CAS  PubMed  Google Scholar 

  31. Melamed, E., Hefti, F. and Wurtman, R. J. (1980). Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in Parkinsonism. Ann. Neurol, 8, 558–563

    CAS  PubMed  Google Scholar 

  32. Poirier, L. J., Filion, M., Larochelle, L. and Pecharde, J-C. (1976). Physiopathology of tremor and rigidity. In Birkmayer, W. and Hornykiewicz, O. (eds.) Advances in Parkinsonism, pp. 217–235. (Basle: Roche)

    Google Scholar 

  33. Eadie, M. J. and Sutherland, J. M. (1964). Arteriosclerosis in Parkinsonism. J. Neurol. Neurosurg. Psychiatry, 27, 237–240

    CAS  PubMed  Google Scholar 

  34. Alvord, E. C. Jr. (1968). The pathology of Parkinsonism. In Minckler, J. (ed.) Pathology of the Nervous System. Vol. 1, pp. 1152–1161. (New York: McGraw-Hill)

    Google Scholar 

  35. Oppenheimer, D. R. (1976). Diseases of the basal ganglia, cerebellum and motor neurons. In Blackwood, W. and Corsellis, J. A. N. (eds.) Greenfield’s Neuropathology. 3rd Edn. pp. 608–651. (London: Arnold)

    Google Scholar 

  36. Bird, E. D. (1980). Chemical pathology of Huntington’s disease. Annu. Rev. Pharmacol Toxicol, 20, 533–551

    CAS  PubMed  Google Scholar 

  37. Shoulson, I., Kartzinel, R. and Chase, T. N. (1976). Huntington’s disease: treatment with dipropylacetic acid and gamma-aminobutyric acid. Neurology, 26, 61–63

    CAS  PubMed  Google Scholar 

  38. Perry, T. L., Wright, J. M., Hansen, S., Allan, B. M., Baird, P. A. and MacLeod, P. M. (1980). Failure of aminooxyacetic acid therapy in Huntington’s disease. Neurology, 30, 772–775

    CAS  PubMed  Google Scholar 

  39. Manyam, B. V, Katz, L., Hare, T. A., Kaniefski, K. and Tremblay, R. D. (1981). Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington’s disease. Ann. Neurol, 10, 35–37

    CAS  PubMed  Google Scholar 

  40. Butterfield, D. A., Oeswein, J. Q., Prunty, M. E., Hisle, K. C. and Markesbery, W. R. (1978). Increased sodium plus potassium adenosine triphosphatase activity in erythrocyte membranes in Huntington’s disease. Ann. Neurol, 4, 60–62

    CAS  PubMed  Google Scholar 

  41. Mann, J. and Chiu, E. (1978). Platelet monoamine oxidase activity in Huntington’s chorea. J. Neurol, Neurosurg. Psychiatry, 41, 809–812

    CAS  Google Scholar 

  42. Ando, N., Gold, B. I., Bird, E. D. and Roth, R. H. (1979). Regional brain levels of γ-hydroxybutyrate in Huntington’s disease. J. Neurochem., 32, 617–622

    CAS  PubMed  Google Scholar 

  43. Bird, E. D., Gale, J. S. and Spokes, E. G. (1977). Huntington’s chorea: postmortem activity of enzymes involved in cerebral glucose metabolism. J. Neurochem., 29, 539–545

    CAS  PubMed  Google Scholar 

  44. Urquhart, N., Perry, T. L., Hansen, S. and Kennedy, J. (1975). GABA content and glutamic acid decarboxylase activity in brain of Huntington’s chorea patients and control subjects. J. Neurochem., 24, 1071–1075

    CAS  PubMed  Google Scholar 

  45. Nausieda, P. A., Koller, W. C., Weiner, W. J. and Klawans, H. L. (1979). Chorea induced by oral contraceptives. Neurology, 29, 1605–1609

    CAS  PubMed  Google Scholar 

  46. Dreese, M. J. and Netsky, M. G. (1968). Degenerative disorders of the basal ganglia. In Minckler, J. (ed.) Pathology of the Nervous System. Vol. 1, pp. 1185–1204. (New York: McGraw-Hill)

    Google Scholar 

  47. Corsellis, J. A. N. (1976). Ageing and the dementias. In Blackwood, W. and Corsellis, J. A. N. (eds.) Greenfield’s Neuropathology. 3rd Edn., pp. 796–848. (London: Arnold)

    Google Scholar 

  48. Martin, J. P. (1959). Remarks on the functions of the basal ganglia. Lancet, 1, 999–1005

    CAS  PubMed  Google Scholar 

  49. Goetz, C. G., Weiner, W. J. and Klawans, H. L. (1981). Treatment of the choreas. In Barbeau, A. (ed.) Disorders of Movement, pp. 29–41. (Lancaster: MTP Press)

    Google Scholar 

  50. Baldessarini, R. J. and Tarsy, D. (1979). Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Int. Rev. Neurobioi, 21, 1–45

    CAS  Google Scholar 

  51. Gerlach, J. (1979). Tardive dyskinesia. Danish Med. J., 46, 209–245

    Google Scholar 

  52. Snyder, S. H. (1979). Receptors, neurotransmitters and drug responses. N. Engl. J. Med., 300, 465–472

    CAS  PubMed  Google Scholar 

  53. Weiss, B., Greenberg, L. and Cantor, E. (1979). Age-related alterations in the development of adrenergic denervation supersensitivity. Fed. Proc, 38, 1915–1921

    CAS  PubMed  Google Scholar 

  54. Klawans, H. L. (1973). The Pharmacology of Extrapyramidal Movement Disorders. (Basel: Karger)

    Google Scholar 

  55. Creese, I. and Sibley, D. R. (1981). Receptor adaptations to centrally acting drugs. Annu. Rev. Pharmacol. Toxicol., 21, 357–391

    CAS  PubMed  Google Scholar 

  56. Paulson, G. W. (1981). Treatment of tardive dyskinesia. In Barbeau, A. (ed.) Disorders of Movement, pp. 133–150. (Lancaster: MTP Press)

    Google Scholar 

  57. Wurtman, R. J., Hefti, F. and Melamed, E. (1981). Precursor control of neurotransmitter synthesis. Pharmacol. Rev., 32, 315–335

    Google Scholar 

  58. Eldridge, R., Kanter, W. and Koerber, T. (1973). Levodopa in dystonia. Lancet, 2, 1027–1028

    Google Scholar 

  59. Tolosa, E. S. (1981). Clinical features of Meige’s disease (idiopathic orofacial dystonia). A report of 17 cases. Arch. Neurol., 38, 147–151

    CAS  PubMed  Google Scholar 

  60. Tolosa, E. S. and Lai, C. (1979). Meige disease: striatal dopaminergic preponderance. Neurology, 29, 1126–1130

    CAS  PubMed  Google Scholar 

  61. Casey, D. E. (1980). Pharmacology of blepharospasm-oromandibular dystonia syndrome. Neurology, 30, 690–695

    CAS  PubMed  Google Scholar 

  62. Snyder, S. H. (1981). Dopamine receptors, neuroleptics and schizophrenia. Am. J. Psychiatry, 138, 460–464

    CAS  PubMed  Google Scholar 

  63. Bird, E. D., Spokes, E. G. S. and Iversen, L. I. (1980). Dopamine and noradrenaline in postmortem brain in Huntington’s disease and schizophrenic illness. Acta Psychiatr. Scand., 61 (Suppl. 280), 63–72

    Google Scholar 

  64. Fujita, K., Ito, T., Maruta, K., Teradaira, R., Beppu, H., Nakagami, Y., Kato, Y., Nagatsu, T. and Kato, T. (1978). Serum dopamine-γ-hydroxylase in schizophrenic patients. J. Neurochem., 30, 1569–1572

    CAS  PubMed  Google Scholar 

  65. Leonard, B. E. (1975). Neurochemical and neuropharmacological aspects of depression. Int. Rev. Neurobioi, 18, 357–387

    CAS  Google Scholar 

  66. Maggi, A. and Enna, S. J. (1980). Regional alteration in rat brain neurotransmitter systems following chronic lithium treatment. J. Neurochem., 34, 888–892

    CAS  PubMed  Google Scholar 

  67. Zis, A. P. and Goodwin, F. K. (1979). Novel antidepressants and the biogenic amine hypothesis of depression. The case for iprindole and mianserin. Arch. Gen. Psychiatry, 36, 1097–1107

    CAS  PubMed  Google Scholar 

  68. Sandler, M., Ruthven, C. R. J., Goodwin, B. L., Reynolds, G. P., Rao, V. A. R. and Cohen, A. (1980). Trace amine deficit in depressive illness: the phenylalanine connexion. Acta Psychiatr. Scand., 61 (Suppl. 280), 29–38

    Google Scholar 

  69. Sulser, F., Vetulani, J. and Mobley, P. L. (1977). Mode of action of antidepressant drugs. Biochem. Pharmacol., 27, 257–261

    Google Scholar 

  70. Coppen, A. and Wood, K. M. (1980). Peripheral serotonergic and adrenergic responses in depression. Acta Psychiatr. Scand., 61 (Suppl. 280), 21–27

    Google Scholar 

  71. Herskovitz, E. and Blackwood, W. (1969). Essential (familial) tremor — a case report. J. Neurol., Neurosurg. Psychiatry, 32, 509–511

    Google Scholar 

  72. Murray, T. J. (1981). Essential tremor. In Barbeau, A. (ed.) Disorders of Movement, pp. 151–170. (Lancaster: MTP Press)

    Google Scholar 

  73. Van Praag, H. M. and De Haan, S. (1980). Central serotonin deficiency — a factor which increases depression vulnerability. Acta Psychiatr. Scand., 61 (Suppl. 280), 89–95

    Google Scholar 

  74. Gillin, J. C., Mendelson, W. B., Sitaram, N. and Wyatt, R. J. (1978). The neuropharmacology of sleep and wakefulness. Annu. Rev. Pharmacol. Toxicol., 18, 563–579

    CAS  PubMed  Google Scholar 

  75. Wyler, A. R., Wilkus, R. J. and Troupin, A. S. (1975). Methysergide in the treatment of narcolepsy. Arch. Neurol., 32, 265–268

    CAS  PubMed  Google Scholar 

  76. Growdon, J. H., Shahani, B. T. and Young, R. R. (1976). L-5-Hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. Neurology, 26, 1135–1140

    CAS  PubMed  Google Scholar 

  77. Magnussen, I., Dupont, E., Prange-Hansen, A. and De Fine Olivarius, B. (1977). Palatal myoclonus treated with 5-hydroxytryptophan and a decarboxylase inhibitor. Acta Neurol. Scand., 55, 251–253

    CAS  PubMed  Google Scholar 

  78. Fennessy, M. R. and Lee, J. R. (1972). The effects of benzodiazepines on brain amines in the mouse. Arch. Intern. Pharmacodyn., 197, 37–44

    CAS  Google Scholar 

  79. Jenner, P., Chadwick, D., Reynolds, E. H. and Marsden, C. D. (1975). Altered 5HT metabolism with clonazepam, diazepam and diphenylhydantoin. J. Pharm. Pharmacol, 27, 707–710

    CAS  PubMed  Google Scholar 

  80. Goldberg, M. A. and Dorman, J. D. (1976). Intention myoclonus successfully treated with clonazepam. Neurology, 26, 24–26

    Google Scholar 

  81. Lance, J. W. (1981). Headache. Ann. Neurol., 10, 1–10

    CAS  PubMed  Google Scholar 

  82. Lance, J. W. (1978). Migraine. In Matthews, W. B. and Glaser, G. H. (eds.) Recent Advances in Clinical Neurology. Vol. 2, pp. 145–161. (Edinburgh: Churchill-Livingstone)

    Google Scholar 

  83. Bruyn, G. W. (1976). The biochemical basis of migraine: a critique. In Klawans, H. (ed.) Clinical Neuropharmacology. Vol. 1, pp. 185–213. (New York: Raven Press)

    Google Scholar 

  84. Hardebo, J. E., Edvinsson, L., Owman, C. H. and Svendgaard, N-Aa. (1978). Potentiation and antagonism of serotonin effects on intracranial and extracranial vessels. Neurology, 28, 64–70

    CAS  PubMed  Google Scholar 

  85. Murphy, D. L. (1978). Substrate-selective monoamine oxidases-inhibitor, tissue, species and functional differences. Biochem. Pharmacol., 27, 1889–1893

    CAS  PubMed  Google Scholar 

  86. Sandler, M., Reveley, M. A. and Glover, V. (1981). Human platelet monoamine oxidase activity in health and disease: a review. J. Clin. Pathol., 34, 292–302

    CAS  PubMed  Google Scholar 

  87. Somerville, B. W. (1976). Platelet-bound and free serotonin levels in jugular and forearm venous blood during migraine. Neurology, 26, 41–45

    CAS  PubMed  Google Scholar 

  88. Sicuteri, F. (1976). Migraine, a central biochemical dysnocioception. Headache, 16, 145–159

    CAS  PubMed  Google Scholar 

  89. Anthony, M., Hinterberger, H. and Lance, J. W. (1967). Plasma serotonin in migraine and stress. Arch. Neurol., 16, 544–552

    CAS  PubMed  Google Scholar 

  90. Regoli, D. and Barabe, J. (1980). Pharmacology of bradykinin and related kinins. Pharmacol Rev., 32, 1–46

    CAS  PubMed  Google Scholar 

  91. Hanington, E. (1978). Migraine: a blood disorder. Lancet, 2, 501–502

    CAS  PubMed  Google Scholar 

  92. Sandler, M., Youdim, M. B. H. and Hanington, E. (1974). A phenylethylamine oxidising defect in migraine. Nature (London), 250, 335–337

    CAS  PubMed  Google Scholar 

  93. Glover, V., Sandler, M., Grant, E., Rose, F. C., Orton, D., Wilkinson, M. and Stevens, D. (1977). Transitory decrease in platelet monoamine-oxidase activity during migraine attacks. Lancet, 1, 391–393

    CAS  PubMed  Google Scholar 

  94. Sandler, M. (1978). Implications of the platelet monoamine oxidase deficit during migraine attacks. Res. Clin. Stud. Headache, 6, 65–72

    CAS  PubMed  Google Scholar 

  95. Masel, B. E., Chesson, A. L., Peters, B. H., Levin, H. S. and Alperin, J. B. (1980). Platelet antagonists in migraine prophylaxis. A clinical trial using aspirin and dipyridamole. Headache, 20, 13–18

    CAS  PubMed  Google Scholar 

  96. Moncada, S. and Vane, J. R. (1979). Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev., 30, 293–331

    Google Scholar 

  97. Sandler, M. (1972). Migraine: a pulmonary disease? Lancet, 1, 618–619

    CAS  PubMed  Google Scholar 

  98. Neligan, P., Harriman, D. G. F. and Pearce, J. (1977). Respiratory arrest in familial hemiplegic migraine: a clinical and neuropathological study. Br. Med. J., 2, 732–734

    CAS  PubMed Central  PubMed  Google Scholar 

  99. Raskin, N. H. (1981). Pharmacology of migraine. Annu. Rev. Pharmacol Toxicol, 21, 463–478

    CAS  PubMed  Google Scholar 

  100. Symonds, C. P. (1956). A particular variety of headache. Brain, 79, 217–232

    CAS  PubMed  Google Scholar 

  101. Anthony, M. and Lance, J. W. (1971). Whole blood histamine and plasma serotonin in cluster headache. Arch. Neurol, 25, 225–231

    CAS  PubMed  Google Scholar 

  102. Andrews, P. R. and Johnston, G. A. R. (1979). GABA agonists and antagonists. Biochem. Pharmacol, 28, 2697–2702

    CAS  PubMed  Google Scholar 

  103. Iversen, L. L. and Kelly, J. S. (1975). Uptake and metabolism of γ-aminobutyric acid by neurones and glial cells. Biochem. Pharmacol., 24, 933–938

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Queensland, Brisbane, Australia

    M. J. Eadie

Authors
  1. M. J. Eadie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. H. Tyrer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1983 M. J. Eadie and J. H. Tyrer

About this chapter

Cite this chapter

Eadie, M.J., Tyrer, J.H. (1983). Disturbances of synaptic transmission. In: Biochemical Neurology. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-0896-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-0896-8_5

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-017-0898-2

  • Online ISBN: 978-94-017-0896-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation